Theravance Newswire

Comprehensive Real-Time News Feed for Theravance.

Results 1 - 20 of 79 in Theravance

  1. "Theravance, Inc. (THRX) - Financial and Strategic SWOT Analysis Review" PublishedRead the original story

    Saturday Jan 17 | PR-inside.com

    Theravance, Inc. is a biopharmaceutical company. The company discovers, develops and commercializes small molecule medicines.

    Comment?

  2. Stocks Coverage on the Pharma Industry -- Mylan, Salix Pharma, Zoetis, Theravance, and CempraRead the original story

    Friday Jan 9 | Sys-Con Media

    Investor-Edge has initiated coverage on the following equities: Mylan Inc. , Salix Pharmaceuticals Ltd , Zoetis Inc. , Theravance Inc. , and Cempra Inc. . Free research on these five companies can be accessed at: http://investor-edge.com/register , the NASDAQ Composite ended at 4,736.19, up 1.84%, the Dow Jones Industrial Average advanced 1.84%, to finish the day at 17,907.87, and the S&P 500 closed at 2,062.14, up 1.79%.

    Comment?

  3. Theravance Biopharma Announces New Employment Inducement AwardsRead the original story

    Monday Jan 5 | BioSpace

    Theravance Biopharma, Inc. announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that stock options to purchase an aggregate of 114,500 of the Company's ordinary shares were granted to seven new non-executive officer employees on January 2, 2015. The options were granted in accordance with NASDAQ Listing Rule 5635 under the Theravance Biopharma, Inc. 2014 New Employee Equity Incentive Plan , which the Board of Directors of Theravance Biopharma adopted in October 2014 to facilitate the granting of equity awards to new employees.

    Comment?

  4. Theravance Receives Average Recommendation of "Hold" from BrokeragesRead the original story

    Wednesday Dec 31 | AmericanBankingNews.com

    Shares of Theravance have received an average rating of "Hold" from the eight analysts that are presently covering the stock, Analyst Ratings.Net reports . Two investment analysts have rated the stock with a sell rating and six have assigned a hold rating to the company.

    Comment?

  5. Theravance Receives Average Recommendation of "Hold" from BrokeragesRead the original story

    Wednesday Dec 31 | AmericanBankingNews.com

    Shares of Theravance have received an average rating of "Hold" from the eight analysts that are presently covering the stock, Analyst Ratings.Net reports . Two investment analysts have rated the stock with a sell rating and six have assigned a hold rating to the company.

    Comment?

  6. Express Scripts presses for expansion of drugs it won't coverRead the original story

    Dec 24, 2014 | Business Insurance

    ... Other drugmakers without potentially transformative new products, such as Shire P.L.C., Novo Nordisk and Theravance Inc., may also be particularly vulnerable, analysts said. Neither Shire, Novo Nordisk nor Theravance responded to requests for ...

    Comment?

  7. Exclusive: Express Scripts presses for expansion of drugs it won't coverRead the original story

    Dec 23, 2014 | Reuters

    ... insurers. Other drugmakers without potentially transformative new products, such as Shire Plc, Novo Nordisk and Theravance Inc, may also be particularly vulnerable, analysts said. Neither Shire, Novo Nordisk nor Theravance responded to requests for ...

    Comment?

  8. RPT - EXCLUSIVE-Express Scripts presses for more drug savings with coverage listRead the original story w/Photo

    Dec 23, 2014 | AlertNet

    ... insurers. Other drugmakers without potentially transformative new products, such as Shire Plc, Novo Nordisk and Theravance Inc , may also be particularly vulnerable, analysts said. Neither Shire, Novo Nordisk nor Theravance responded to requests for ...

    Comment?

  9. Exclusive: Express Scripts presses for more drug savings with coverage listRead the original story

    Dec 22, 2014 | Reuters

    ... insurers. Other drugmakers without potentially transformative new products, such as Shire Plc, Novo Nordisk and Theravance Inc, may also be particularly vulnerable, analysts said. Neither Shire, Novo Nordisk nor Theravance responded to requests for ...

    Comment?

  10. REMINDER: To Host Investor And Analyst Day On December 12thRead the original story

    Dec 9, 2014 | BioSpace

    Theravance Biopharma, Inc. announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., a reminder that the Company will host an Investor and Analyst Day for the investment community on Friday, December 12, 2014 from 8:30 am to 11:30 am EST in New York, NY. Management will present updates regarding the post-split business outlook, commercial strategy for VIBATIV , and key development programs.

    Comment?

  11. REMINDER: Theravance Biopharma to Host Investor and Analyst Day on December 12thRead the original story w/Photo

    Dec 9, 2014 | Market Wire

    : TBPH ) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., a reminder that the Company will host an Investor and Analyst Day for the investment community on Friday, ...

    Comment?

  12. California Healthcare Institute (CHI) And BayBio (Bay Area Bioscience ...Read the original story

    Dec 7, 2014 | BioSpace

    ... to be completed by end of the first quarter of 2015. Rick Winningham, chairman and chief executive officer of Theravance BioPharma and chairman of CHI, will become the initial chairman of CBI upon completion of the merger. Hal Van Wart, Ph.D., ...

    Comment?

  13. California Healthcare Institute and Bay Area Bioscience Association...Read the original story

    Dec 8, 2014 | Freshnews

    ... to be completed by end of the first quarter of 2015. Rick Winningham, chairman and chief executive officer of Theravance BioPharma and chairman of CHI, will become the initial chairman of CBI upon completion of the merger. Hal Van Wart, Ph.D., ...

    Comment?

  14. Theravance Biopharma Announces New Employment Inducement AwardsRead the original story

    Dec 4, 2014 | BioSpace

    Theravance Biopharma, Inc. announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that stock options to purchase an aggregate of 104,800 of the Company's ordinary shares were granted to ten new non-executive officer employees on December 1, 2014. The options were granted in accordance with NASDAQ Listing Rule 5635 under the Theravance Biopharma, Inc. 2014 New Employee Equity Incentive Plan , which the Board of Directors of Theravance Biopharma adopted in October 2014 to facilitate the granting of equity awards to new employees.

    Comment?

  15. Dividend Dogs Of Healthcare: A 29.17% Advantage For The 5 Lowest Price High Yield StocksRead the original story w/Photo

    Dec 4, 2014 | Seeking Alpha

    ... sector stocks by yield were two biotechnology firms, PDL BioPharma, Inc. (NASDAQ: PDLI ) [1], and in second, Theravance Inc. (NASDAQ: THRX ) [2]. One drug delivery firm took fourth, PetMed Express (NASDAQ: PETS ) [4]. A lone diagnostic substances ...

    Comment?

  16. Theravance Biopharma Announces New Employment Inducement AwardsRead the original story

    Dec 3, 2014 | Freshnews

    Theravance Biopharma, Inc. announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that stock options to purchase an aggregate of 104,800 of the Company's ordinary shares were granted to ten new non-executive officer employees on December 1, 2014. The options were granted in accordance with NASDAQ Listing Rule 5635 under the Theravance Biopharma, Inc. 2014 New Employee Equity Incentive Plan , which the Board of Directors of Theravance Biopharma adopted in October 2014 to facilitate the granting of equity awards to new employees.

    Comment?

  17. Theravance Downgraded by Leerink SwannRead the original story

    Dec 2, 2014 | AmericanBankingNews.com

    Shares of Theravance opened at 14.00 on Tuesday. Theravance has a 1-year low of $12.78 and a 1-year high of $32.8928.

    Comment?

  18. Theravance Biopharma To Host Investor And Analyst Day On December 12thRead the original story

    Nov 25, 2014 | BioSpace

    Theravance Biopharma, Inc. announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that the Company will host an Investor and Analyst Day for the investment community on Friday, December 12, 2014 from 8:30 am to 11:30 am EST in New York, NY. Management will present updates regarding the post-split business outlook, commercial strategy for VIBATIV , and key development programs.

    Comment?

  19. Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and TheravanceRead the original story

    Nov 26, 2014 | Sys-Con Media

    Investor-Edge has initiated coverage on the following equities: VIVUS Inc. , Horizon Pharma PLC , Endocyte Inc. , Johnson and Johnson , and Theravance Inc. . Free research on these five companies can be accessed at: http://investor-edge.com/register , the NASDAQ Composite ended at 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% lower, to finish the day at 17,814.94, and the S&P 500 closed at 2,067.03, down 0.12%.

    Comment?

  20. Theravance Biopharma to Host Investor and Analyst Day on December 12thRead the original story

    Nov 20, 2014 | Freshnews

    Theravance Biopharma, Inc. announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that the Company will host an Investor and Analyst Day for the investment community on Friday, December 12, 2014 from 8:30 am to 11:30 am EST in New York, NY. Management will present updates regarding the post-split business outlook, commercial strategy for VIBATIV , and key development programs.

    Comment?